Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-line rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years w...

Descripción completa

Detalles Bibliográficos
Autores principales: Camus, Vincent, Belot, Aurélien, Oberic, Lucie, Sibon, David, Ghesquières, Hervé, Thieblemont, Catherine, Fruchart, Christophe, Casasnovas, Olivier, Michot, Jean-Marie, Molina, Thierry Jo, Bosly, André, Joubert, Clémentine, Haioun, Corinne, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Fitoussi, Olivier, Delarue, Richard, Tilly, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772793/
https://www.ncbi.nlm.nih.gov/pubmed/35737565
http://dx.doi.org/10.1182/bloodadvances.2022007609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772793/
https://www.ncbi.nlm.nih.gov/pubmed/35737565
http://dx.doi.org/10.1182/bloodadvances.2022007609

Ejemplares similares